These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19618717)

  • 1. [Role of PKCbeta in the malignant tumors and enzastaurin, a PKCbeta inhibitor].
    Li XY; Chen XG
    Yao Xue Xue Bao; 2009 May; 44(5):449-55. PubMed ID: 19618717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
    Herbst RS; Oh Y; Wagle A; Lahn M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
    Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
    Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
    Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
    J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzastaurin.
    Ma S; Rosen ST
    Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of protein kinase Cbeta prevents foam cell formation by reducing scavenger receptor A expression in human macrophages.
    Osto E; Kouroedov A; Mocharla P; Akhmedov A; Besler C; Rohrer L; von Eckardstein A; Iliceto S; Volpe M; Lüscher TF; Cosentino F
    Circulation; 2008 Nov; 118(21):2174-82. PubMed ID: 18981301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase C-beta as a therapeutic target in breast cancer.
    Sledge GW; Gökmen-Polar Y
    Semin Oncol; 2006 Jun; 33(3 Suppl 9):S15-8. PubMed ID: 16797377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
    Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
    Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway.
    Jiang XH; Lam SK; Lin MC; Jiang SH; Kung HF; Slosberg ED; Soh JW; Weinstein IB; Wong BC
    Oncogene; 2002 Sep; 21(39):6113-22. PubMed ID: 12203123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
    Wang Y; An R; Dong X; Pan S; Duan G; Sun X
    Urol Int; 2009; 82(2):214-21. PubMed ID: 19322013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
    Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
    Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
    Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
    Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
    Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
    J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
    Nakamura S; Chikaraishi Y; Tsuruma K; Shimazawa M; Hara H
    Exp Eye Res; 2010 Jan; 90(1):137-45. PubMed ID: 19825373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.
    Baumann P; Armann J; Mandl-Weber S; Grün G; Oduncu F; Schmidmaier R
    Eur J Haematol; 2008 Jan; 80(1):37-45. PubMed ID: 18028419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.